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Anaphylaxis is an acute, severe, and potentially fatal
systemic allergic reaction. Immunoglobulin E (IgE),
mast cells, and histamine have long been associated
with anaphylaxis, but an alternative pathway medi-
atedby IgGhasbeensuggested tobemore important
in the elicitation of anaphylaxis. Here,we showed that
basophils, the least common blood cells, were dis-
pensable for IgE-mediated anaphylaxis but played
a critical role in IgG-mediated, passive and active
systemic anaphylaxis in mice. In vivo depletion of
basophils but not macrophages, neutrophils, or NK
cells ameliorated IgG-mediated passive anaphylaxis
and rescued mice from death in active anaphylaxis.
Upon capture of IgG-allergen complexes, basophils
released platelet-activating factor (PAF), leading to
increased vascular permeability. These results high-
light a pivotal role for basophils in vivo and contrast
two major, distinct pathways leading to allergen-in-
duced systemic anaphylaxis: one mediated by baso-
phils, IgG, andPAF and the other ‘‘classical’’ pathway
mediated by mast cells, IgE, and histamine.
INTRODUCTION
Anaphylaxis is a rapid-onset, life-threatening allergic reaction
and is most commonly triggered by exposure to allergens such
as insect venoms, foods, and medications (Sampson et al.,
2006; Simons et al., 2007). Immunoglobulin E (IgE) andmast cells
have long been associated with anaphylaxis (Bochner and
Lichtenstein, 1991; Galli, 2005; Kemp and Lockey, 2002). In indi-
viduals sensitized with a given allergen, IgE antibodies are
produced against the allergen and bind to high-affinity IgE
receptor Fc3RI expressed on mast cells (Kraft and Kinet, 2007).
Upon binding of the allergen, IgE-Fc3RI complexes onmast cells
are crosslinked, thereby leading to mast cell activation. Acti-
vated mast cells undergo degranulation and release chemical
mediators, such as histamine, prostaglandin D2, and leukotriene
C4, that are responsible for the development of anaphylacticmanifestations (Bochner and Lichtenstein, 1991; Galli, 2005;
Kemp and Lockey, 2002). Histamine acts on endothelial cells
to increase vascular permeability and also causes constriction
of intestinal and bronchial smooth muscle (Winbery and
Lieberman, 2002).
Various studies indicate that this classical pathway does not
account for all anaphylactic responses. Active systemic anaphy-
laxis could be induced even in mice deficient for mast cells, IgE,
or Fc3RIa chain (Dombrowicz et al., 1997; Jacoby et al., 1984;
Miyajima et al., 1997; Oettgen et al., 1994; Strait et al., 2002),
demonstrating that neither mast cells nor IgE are essential for
the development of allergen-induced anaphylaxis. In contrast,
FcRg-chain-deficient mice that lack the expression of Fc3RI
and stimulatory IgG receptors manifested no apparent sign of
active systemic anaphylaxis (Miyajima et al., 1997), suggesting
that IgG plays an important role in active anaphylaxis. Indeed,
passive sensitization with allergen-specific IgG, particularly
IgG1 subclass, conferred onmice the ability to develop systemic
anaphylaxis upon exposure to the allergen (Dombrowicz et al.,
1997; Miyajima et al., 1997). Pretreatment of mice with FcgRII-
III mAb blocked active systemic anaphylaxis (Strait et al.,
2002), indicating that the low-affinity IgG receptor FcgRIII is
mainly involved in IgG-mediated systemic anaphylaxis. All these
results strongly suggest that systemic anaphylaxis is predomi-
nantly mediated by nonmast cells, IgG, and FcgRIII, in contrast
to the traditional thought (Finkelman, 2007). However, cells
responsible for IgG-mediated systemic anaphylaxis have
remained elusive, although a previous study suggested that
macrophages are probably the major cell type contributing to
IgG-mediated anaphylaxis (Strait et al., 2002).
Basophils represent less than 1% of peripheral blood leuko-
cytes and share several features with tissue-resident mast cells,
such as the surface expression of Fc3RI and the release of chem-
ical mediators upon stimulation (Falcone et al., 2000; Galli, 2000;
Prussin and Metcalfe, 2003). Therefore, basophils are often
considered to be minor and possibly redundant ‘‘circulating
mast cells’’ and are analyzed as a surrogate of the less accessi-
ble tissue mast cells. The recent finding that basophils readily
generate large quantities of T helper 2 (Th2) cytokines such as
IL-4 and IL-13 has provided new insights into the possible roles
for basophils in allergic diseases and immunity to pathogens
(Min et al., 2004; Voehringer et al., 2004).Immunity 28, 581–589, April 2008 ª2008 Elsevier Inc. 581
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Basophils Elicit Anaphylaxis via IgG but Not IgEWe previously demonstrated that basophils play a critical role
in the development of IgE-mediated chronic allergic inflamma-
tion, independently of T cells and mast cells (Mukai et al.,
2005; Obata et al., 2007). A single subcutaneous injection of
multivalent allergens elicited not only immediate- and late-phase
ear swelling but also delayed-onset ear swelling with massive
eosinophil infiltration in mice that had been passively sensitized
with antigen-specific IgE. Mast-cell-deficient mice could also
develop the delayed-onset ear swelling, whereas treatment of
mice with a newly developed basophil-depleting mAb Ba103
specific to CD200R3 (Kojima et al., 2007) prior to the allergen
challenge completely abolished the IgE-mediated chronic
allergic inflammation (Obata et al., 2007), even though basophils
accounted for only 2% of the infiltrates in the skin lesions
(Mukai et al., 2005). The Ba103 treatment during the progression
of the dermatitis showed a therapeutic effect on the inflammation
and resulted in drastic reduction in numbers of infiltrating
eosinophils and neutrophils, concomitantly with elimination of
basophils from the skin lesions. Thus, basophils play a pivotal
and nonredundant role in the development of IgE-mediated
chronic allergic inflammation, as an initiator rather than as an
effector (Obata et al., 2007). This finding prompted us to examine
whether basophils also play a nonredundant role in immediate-
type allergic responses, distinctively from mast cells.
In the present study, we explored the possible roles for baso-
phils in IgE- and IgG-mediated passive systemic anaphylaxis, as
well as in active systemic anaphylaxis, by treating mice with the
basophil-depleting mAb. Our results demonstrated that baso-
phils are dispensable for IgE-mediated anaphylaxis and that
basophiles but not other cells, including macrophages, are the
main contributor to IgG-mediated anaphylaxis through release
of platelet-activating factor (PAF) instead of histamine.
RESULTS
Basophils Efficiently Capture Allergen-IgG1 Complexes
To clarify the pathogenesis of and cells responsible for IgG-me-
diated anaphylaxis, we have established a simple model of
penicillin shock, in which mice were passively sensitized with
penicillin V (PenV)-specific IgG1 mAbs and then challenged
with intravenous injection of PenV-conjugated bovine-serum
albumin (PenV-BSA). Both normal and mast-cell-deficient
(KitW-sh/W-sh) mice developed systemic anaphylaxis, as judged
by a drastic drop in rectal temperature, although the depres-
sion in temperature was slightly less in the latter than the former
(Figure 1A). Thus, mast cells were dispensable for PenV-
specific, IgG1-mediated anaphylaxis, although they appeared
to make some contribution to it, in accord with previous reports
on another mast-cell-deficient mouse, WBB6F1-KitW/W-v, sensi-
tized with DNP-specific IgG1 (Dombrowicz et al., 1997; Miyajima
et al., 1997).
For acute allergic reactions to be elicited, we expected that the
cells responsible for IgG1-mediated anaphylaxis would capture
the IgG1-allergen complexes immediately after the allergen
challenge. Flow-cytometric analysis of samples frommice sensi-
tized with PenV-specific IgG1 demonstrated that many cell
types, including NK cells, macrophages, monocytes, dendritic
cells, neutrophils, eosinophils, basophils, and mast cells (but
not T cells and platelets), displayed PenV-BSA on their surface582 Immunity 28, 581–589, April 2008 ª2008 Elsevier Inc.(Figure 1B). Among these cells, basophils bound the greatest
amount of allergen per cell, and the binding was strongly
inhibited in mice treated with FcgRII-III mAb prior to the IgG1
sensitization (Figure 1B, bottom panels, gray line). These results
suggested that basophils can efficiently capture the IgG1-aller-
gen complexes via FcgRII-III expressed on their surface,
although we could not formally exclude the possibility that other
cell types captured the complexes evenmore efficiently and then
quickly internalized them within a minute after the allergen
challenge.
Figure 1. Basophils Capture the Highest Amount of Immune
Complexes in PenV-Specific, IgG1-Mediated Systemic Anaphylaxis
(A) Wild-type and mast cell-deficient (KitW-sh/W-sh) C57BL/6 mice were
passively sensitized with PenV-specific IgG1 mAbs and then challenged
with PenV-BSA (closed circles) or control BSA (open circles). Change in rectal
temperature over time after allergen challenge is shown. Data are expressed
as the mean ± SD (n = 5 in wild-type, and n = 3 in KitW-sh/W-sh) and are repre-
sentative of five independent experiments.
(B) C57BL/6 mice passively sensitized with anti-PenV IgG1 were challenged
with biotinylated allergens (PenV-BSA or control BSA). Data shown are the
binding of PenV-BSA (histograms with black line) and BSA (shaded
histograms) to various types of cells isolated from mice immediately after
the allergen challenge. Histograms with gray line show the binding of
PenV-BSA when mice were treated with anti-FcgRII-III prior to the IgG1 sensi-
tization. Data are representative of three independent experiments.
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Basophils Elicit Anaphylaxis via IgG but Not IgEIn Vivo Depletion of Basophils Ameliorates
IgG1-Mediated Anaphylaxis
Wenext examined the effect of in vivo depletion of a given cell lin-
eage on the development of IgG1-mediated anaphylaxis to iden-
tify cells responsible for it. We recently established a CD200R3-
specific mAb, Ba103 (Kojima et al., 2007; Obata et al., 2007),
that selectively and reproducibly depletes 80%90% of the
basophils from mouse peripheral blood and spleen after intrave-
nous injection (Figure 2A). Treatment of mice with Ba103 1 day
before the sensitization with anti-PenV IgG1 greatly suppressed
allergen-induced anaphylaxis as judged by the extent of the
rectal temperature drop (Figure 2A, and the titration of allergen
dose is shown in Figure S1 available online). This was also true
for mice that were sensitized with another IgG1 mAb specific to
hapten 2,4,6-trinitrophenol (TNP) and then challenged with
TNP-BSA (Figure S2). Of note, the same treatment with Ba103
had little or no effect on IgE-mediated, TNP-BSA-induced
anaphylaxis (Figure 2A). The suppressive effect of Ba103 on
IgG1-mediated anaphylaxis was also observed in KitW-sh/W-sh
mice (Figure 2A, bottom panels). These results indicated that
basophils are dispensable for IgE-mediated anaphylaxis but
play an essential role in IgG1-mediated anaphylaxis.
To examine the effect of macrophage depletion on IgG1-medi-
ated anaphylaxis, we treated mice with clodronate-liposomes
prior to the allergen challenge. The treatment did not have any
substantial effect on the drop in body temperature in IgG1-medi-
ated anaphylaxis, even though it efficiently eliminated F4/80+
macrophages from the peritoneum and spleen (Figure 2B).
Pretreatment ofmice with anti-NK1.1 greatly reduced the number
of CD49b+IgE NK cells but not of CD49b+IgE+ basophils and
did not affect the IgG1-mediated anaphylaxis (Figure 2C). In
accord with this, IgG1-mediated anaphylaxis could be induced
even in Rag2/Il2rg/ mice that are deficient for NK, NKT, T,
and B cells (data not shown). Furthermore, pretreatment with
anti-Gr-1 had no marked effect on IgG1-mediated anaphylaxis,
although it eliminated almost all the neutrophils (Gr-1hi) and
more than half of the eosinophils (Gr-1loSiglec-F+) from spleen
(Figure 2D), consistent with a previous observation in active
systemic anaphylaxis (Strait et al., 2002). Thus, macrophages,
NK cells, neutrophils, and perhaps eosinophils have little or no
involvement in IgG1-mediated systemic anaphylaxis.
Basophils Release PAF upon Stimulation with
IgG1-Allergen Complexes
The treatment of wild-type and KitW-sh/W-sh mice prior to allergen
challenge with cyproheptadine, an antagonist of histamine and
5-HT, caused partial or no marked blockade of IgG1-mediated
anaphylaxis, respectively (Figure 3A, upper panels), even though
it greatly inhibited IgE-mediated anaphylaxis (Figure 3A, lower
panel). In contrast, treatment with CV6209, a PAF antagonist,
almost completely blocked IgG1-mediated anaphylaxis in both
wild-type and KitW-sh/W-sh mice (Figure 3A, upper panels),
whereas it had much less effect on IgE-mediated anaphylaxis
than did the cyproheptadine treatment (Figure 3A, lower panel).
Thus, PAF rather than histamine is a major chemical mediator in
IgG1-mediated anaphylaxis unlike in an IgE-mediated one.
PAF is one of the most potent and versatile mediators found
in mammals and is produced by a variety of cell types includ-
ing macrophages, neutrophils, eosinophils, basophils, platelets,and endothelial cells (Benveniste, 1974; Prescott et al., 2000).
The finding that both basophils and PAF have major roles in
IgG1-mediated anaphylaxis strongly suggested that basophils
released PAF upon stimulation with IgG1-allergen complexes.
Indeed, the basophil-containing CD49b+ fraction of spleen cells,
but not the basophil-deficient CD49b fraction, released sub-
stantial amounts of PAF (60 pmol/2 3 106 cells/0.5 ml = 120
nM) when stimulated ex vivo with IgG1-allergen complexes
(Figure 3B). The CD49b+ fraction contained NK cells (>90%)
Figure 2. In Vivo Depletion of Basophils but Not Macrophages, NK
Cells, or Neutrophils Ameliorates IgG1-Mediated Anaphylaxis
Wild-type (A–D) and mast-cell-deficient (KitW-sh/W-sh) C57BL/6 mice ([A],
bottom) were treated with Ba103 (A), clodronate-liposomes (B), anti-NK1.1
(C), or anti-Gr-1 (D) for elimination of in vivo basophils, macrophages, NK cells,
or neutrophils, respectively, prior to passive sensitization with anti-PenV IgG1
and challenge with PenV-BSA (A–D) or sensitization with anti-TNP IgE and
challenge with TNP-BSA ([A], middle). Left panels show staining profiles of
spleen cells (A–D) and peritoneal cells ([B], upper panels) from treated and
control mice. Right panels show the time course of change in rectal tempera-
ture (mean ± SD, n = 3 or 4). Data are representative of three or four indepen-
dent experiments.Immunity 28, 581–589, April 2008 ª2008 Elsevier Inc. 583
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Basophils Elicit Anaphylaxis via IgG but Not IgEFigure 3. PAF Is a Major Mediator in
IgG1-Mediated Anaphylaxis and Is Released
from Basophils upon Stimulation with
Immune Complexes
(A) PenV-specific, IgG1-mediated (upper panels),
and TNP-specific, IgE-mediated (lower panel) ana-
phylaxiswere induced inwild-type andKitW-sh/W-sh
C57BL/6mice as for Figure 1.One half hour prior to
allergen challenge, mice were given CV6209
(closed circles), cyproheptadine (closed squares),
or control PBS (open circles). Time course of
change in rectal temperature is shown (mean ±
SD, n = 3 or 4), as a representative of three inde-
pendent experiments.
(B) Basophil-containing CD49b+ fraction and
basophil-deficient CD49b fraction of spleen cells
and peritoneal cells were freshly isolated from
C57BL/6 mice and incubated ex vivo with anti-
PenV IgG1 alone or together with PenV-BSA at
37C for 20 min. The quantity of PAF in culture
supernatants was determined (mean ± SD, n = 3).besides basophils (5%), but the in vivo depletion of NK cells
showed no marked effect on IgG1-mediated anaphylaxis
(Figure 2C), suggesting little or no contribution of NK cells to
PAF production. Peritoneal cells, consisting of 30% macro-
phages and 5% mast cells, released PAF ex vivo upon stim-
ulation with immune complexes, but the amount of PAF was
only 2- to 3-fold greater than the basal amount, in contrast to
an 30-fold increase in the CD49b+ spleen cells (Figure 3B).
Therefore, the PAF released in response to immune complexes
is most probably from basophils.
We next examined the biological activity of PAF released from
activated basophils, by using human umbilical vein endothelial
cells (HUVECs) as an indicator (Bussolino et al., 1987). HUVECs
contracted and lost reciprocal contact, and their stress fibers
became less prominent, when they were incubated with super-
natants from the IgG1-allergen-complex-stimulated CD49b+
fraction but not the CD49b fraction of spleen cells (Figure 4A).
Such morphological changes were similar to those observed
when the cells were stimulated with 10100 nM PAF (Figure 4B),
and they were inhibited by treatment with CV6209 (Figure 4A).
No substantial morphological changes were observed when
the HUVECs were incubated with supernatants from CD49b+
or CD49b spleen cells that were first cultured with IgE plus
allergens (Figure 4C). Moreover, supernatants of peritoneal
macrophages and mast cells incubated with the IgG1-allergen
complexes induced few if any detectable changes in the
HUVECs (Figure 4A). These results strongly suggest that upon
stimulation with the IgG1-allergen complexes, basophils release
PAF, which in turn stimulates endothelial cells to increase vascu-
lar permeability, thereby leading to systemic anaphylaxis.
Indeed, the intravenous injection of 100 ng (200 pmol) PAF
induced a drop in body temperature with the time course and
magnitude comparable to that observed during IgG1-mediated
anaphylaxis (Figure 4D).
Basophil Depletion Rescues Mast-Cell-Deficient Mice
from Anaphylactic Death
We next examined the contribution of basophils to active
systemic anaphylaxis in which wild-type or mast-cell-deficient584 Immunity 28, 581–589, April 2008 ª2008 Elsevier Inc.(KitW-sh/W-sh and KitW/W-v) mice were immunized with PenV-
OVA and 14 days later challenged with intravenous injection of
PenV-BSA (Figure 5 and summarized in Table 1). In contrast to
IgE- or IgG1-mediated passive anaphylaxis, all the mice in any
of the strains died from active anaphylaxis within 15 min.
Treatment of mast-cell-deficient mice with Ba103 before the
allergen challenge rescued them from death, even though
some drop in body temperature was observed (Figure 5 and
Table 1). This suppressive effect of Ba103 was also observed
in another hapten TNP-specific, active systemic anaphylaxis,
in which mast-cell-deficient KitW-sh/W-sh mice were immunized
with TNP-OVA and then challenged with TNP-BSA (Figure S3).
Thus, basophils play a pivotal role in active systemic anaphy-
laxis. Of note, the same treatment with Ba103 failed to rescue
wild-typemice from death (Table 1). Therefore, in allergen-sensi-
tizedmice, both basophils andmast cells appear to contribute to
the pathogenesis of anaphylaxis, most probably in an IgG- and
IgE-dependent manner, respectively.
DISCUSSION
It has long been believed that mast cells and basophils are
involved in classical IgE-mediated systemic anaphylaxis
(Bochner and Lichtenstein, 1991; Galli, 2005; Kemp and Lockey,
2002). The present study clearly demonstrated that basophils
are dispensable for IgE-mediated systemic anaphylaxis in
contrast to mast cells and are instead responsible for IgG1-me-
diated systemic anaphylaxis. Thus, basophils and mast cells
utilize distinct pathways leading to allergen-induced systemic
anaphylaxis: Basophils mainly utilize the IgG-IgG receptor-medi-
ated activating pathways, whereas mast cells predominantly
utilize the IgE-Fc3RI-mediated pathway. The difference between
basophils and mast cells in the elicitation of systemic anaphy-
laxis was observed not only in Ig isotypes and Fc receptors
they utilize but also in chemical mediators they release. Baso-
phils release PAF rather than histamine upon stimulation with
IgG1-allergen complexes, in contrast to mast cells stimulated
with IgE and allergens.
Immunity
Basophils Elicit Anaphylaxis via IgG but Not IgEAprevious study reported thatmast cells were not essential for
the development of IgE-dependent, active systemic anaphylaxis
in a murine model of penicillin shock and suggested that baso-
phils were most probably responsible for it (Choi et al., 1998).
The authors showed that all mice examined, either sufficient or
deficient for mast cells, died from severe anaphylaxis, as we
observed in the present study. Administration of anti-IL-4
completely prevented the fatal reactions in those mice, in which
amounts of PenV-specific IgE but not IgG1 in serum were
drastically reduced. Taken together with their earlier study
(Park et al., 1997), the authors concluded that PenV-induced sys-
temic anaphylaxis totally depended on IgE but not IgG1 and
therefore suggested that basophils instead of mast cells were re-
sponsible for IgE-mediated anaphylaxis. In sharp contrast, we
demonstrated that the in vivo depletion of basophils had no
significant impact on PenV-specific, IgE-mediated passive
anaphylaxis, and others showed that mast cells were essential
for IgE-mediated systemic anaphylaxis (Dombrowicz et al., 1997;
Miyajima et al., 1997). Of note, two types of IgG1 were reported:
onehas anaphylactic activity, and its synthesis is IL-4dependent,
whereas the other lacks this activity, and its synthesis is stimu-
Figure 4. PAF Released by Activated Baso-
phils Induces Morphological Changes
in Endothelial Cells
(A) The CD49b+ and CD49b fractions of C57BL/6
spleen cells, macrophages, and mast cells en-
riched from peritoneal cells were incubated ex
vivo with anti-PenV IgG1 and PenV-BSA as in
Figure 3B. Their culture supernatants were
collected and transferred to monolayer culture of
HUVECs. Photographs show phase-contrast
views (upper panels) and F-actin staining (lower
panels) of HUVECs that were fixed and permeabi-
lized after a half-hour incubation with the culture
supernatants. In some experiments, HUVECs
were treated with CV6209 prior to the addition of
the culture supernatants.
(B) HUVECs in amonolayer culture were incubated
with the indicated concentration of PAF at 37C for
30 min.
(C) The CD49b+ and CD49b fractions of C57BL/6
spleen cells were incubated ex vivo with anti-TNP
IgE and TNP-BSA at 37C for 20 min. Their culture
supernatants were subjected to the assay with
HUVECs as described in (A).
(D) C57BL/6 mice were intravenously injected with
100 ng PAF (closed circles) in 0.2 ml PBS or PBS
alone (open circles). Change in rectal temperature
over time after allergen challenge is shown (mean ±
SD, n = 4), as a representative of three indepen-
dent experiments.
lated by IL-12 and IFNg (Faquim-Mauro
et al., 1999). Furthermore, IL-4 has been
shown to enhance the sensitivity to chem-
ical mediators (Strait et al., 2003). These
observations could well explain the anti-
IL-4-induced suppression of active sys-
temic anaphylaxis even in the presence
of allergen-specific IgG1, and therefore,
the IgE dependency of the anaphylaxis
in this model need to be reexamined. However, we cannot for-
mally exclude the possibility that the difference between poly-
clonal antibodies produced during sensitization for active ana-
phylaxis and monoclonal antibodies used for passive
anaphylaxis might explain in part the discrepancy between our
and previous studies.
Another study demonstrated an important role for macro-
phages in a unique model of active systemic anaphylaxis in
that mice were immunized with goat anti-mouse IgD antiserum
and then challenged with goat IgG (Strait et al., 2002). A single
injection of the antiserum induced the secretion of IL-3 and
IL-4 from T cells, and these cytokines in turn promoted the pro-
duction of large amounts of IgE and IgG antibodies specific to
goat IgG. Intravenous injection of gadolinium chloride (GdCl3)
1 day before the allergen challenge suppressed allergen-
induced anaphylaxis that appeared to be mediated by FcgRIII
and PAF. GdCl3was used to depletemacrophages, even though
no data were presented to confirm such effects. We found that
the GdCl3 treatment with the same protocol as reported did
not show any substantial change in numbers of F4/80+ macro-
phages in the spleen and peritoneum of nonimmunized miceImmunity 28, 581–589, April 2008 ª2008 Elsevier Inc. 585
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Basophils Elicit Anaphylaxis via IgG but Not IgE(data not shown), whereas the clodronate-liposome treatment
efficiently eliminated them, in accord with a recent report
(Nishioka et al., 2007). Importantly, neither clodronate-liposome
nor GdCl3 treatment showed any detectable effect on
IgG1-mediated passive systemic anaphylaxis. Furthermore, the
basophil-containing fraction but not the macrophage-containing
fraction of spleencells releasedsubstantial amountsofPAFwhen
it was incubated ex vivo with allergen-IgG1 immune complexes.
Culture supernatants of the immune-complex-stimulated perito-
neal macrophages showed little or no activity to change themor-
phology of HUVECs, in contrast to those of activated basophils.
Therefore, we concluded that macrophages are not the major
player in IgG1-mediated passive systemic anaphylaxis. On one
hand, our results donot exclude thepossible contributionofmac-
rophages to active systemic anaphylaxis. On the other hand, our
observation, in that in vivo depletion of basophils rescued mast-
cell-deficient mice from death in the PenV-induced, active
systemic anaphylaxis, clearly indicates that basophils play a crit-
ical role in active systemic anaphylaxis. Fc3RIa-deficient mice
reportedly manifested greater severity of IgG1-mediated
anaphylaxis compared to wild-type mice (Dombrowicz et al.,
1997; Miyajima et al., 1997). This phenomenon cannot be easily
understood if IgG1-mediated anaphylaxis is caused by macro-
phages that are negative for Fc3RI. Instead, it could be simply
explained, in case of basophil-mediated anaphylaxis, by en-
hanced expression of basophil FcgRIII, which shares b and g
chains with Fc3RI, in the absence of Fc3RIa chains.
Whatmakes it possible for basophils, the least common leuko-
cytes, to induce systemic anaphylaxis upon exposure to aller-
gens? First, basophils show much higher activity of capturing
allergen-IgG1 complexes than other hematopoietic cells. This
may be attributed to higher expression of the low-affinity IgG
receptors on basophils (Mack et al., 2005). Second, basophils
release PAF upon stimulation with allergen-IgG1 complexes.
PAF increases vascular permeability with 1,000- to 10,000-fold
more potency than histamine (Humphrey et al., 1982). We found
that the intravenous injection of 100 ng (200 pmol) PAF induced
Figure 5. In Vivo Depletion of Basophils Rescues Mast-Cell-
Deficient Mice from Death in Active Systemic Anaphylaxis
We immunized mast-cell-deficient (KitW/W-v and KitW-sh/W-sh) mice with PenV-
OVA and challenged 14 days later with PenV-BSA to induce anaphylaxis. One
day before the allergen challenge, mice were treated with Ba103 (closed
circles) or control IgG (open circles). Left panels show staining profiles of
spleen cells from treated mice. Right panels show the change in rectal temper-
ature over time after the allergen challenge (mean ± s.d., n = 3 or 4). The black
cross indicates death.586 Immunity 28, 581–589, April 2008 ª2008 Elsevier Inc.a drop in body temperature with the time course and magnitude
comparable to that observed during IgG1-mediated anaphy-
laxis. We estimated, on the basis of our in vitro experiment,
that 200 pmol of PAF can be released from 3.3 3 105 basophils,
which is close to the total number of basophils in peripheral
blood, spleen, and bone marrow. Thus, basophils can elicit
systemic anaphylaxis through the release of the potent vaso-
amine PAF upon stimulation with immune complexes, even
though they account for less than 1% of leukocytes in the
body. Basophils may release histamine upon stimulation through
IgE or IgG receptors, but the total amounts of histamine released
from basophils are probably too little to induce systemic anaphy-
laxis, compared to those released from large numbers of mast
cells.
IgG1-mediated anaphylaxis can be induced locally in mice, by
means of intradermal injection of IgG1 mAbs and then intrave-
nous injection of corresponding allergens (Hirayama et al.,
1982). This passive cutaneous anaphylaxis (PCA) is FcgRIII
dependent (Hazenbos et al., 1996) and cannot be elicited in
mast-cell-deficient mice (Arimura et al., 1990). We also
confirmed the mast cell dependency of IgG1-mediated PCA in
our system by using the PenV-specific IgG1 and PenV-BSA
(data not shown). Thus, mast cells are mainly activated in
IgG1-mediated PCA upon exposure to IgG1-allergen com-
plexes. Indeed, peritoneal mast cells were shown to degranulate
when incubated ex vivo with IgG-allergen complexes (Hazenbos
et al., 1996). In contrast, little or no morphological evidence of
degranulation of mast cells was detected in the ear skin, peri-
bronchial tissues, or forestomach during IgG1-mediated pas-
sive systemic anaphylaxis unlike in IgE-mediated anaphylaxis
(Miyajima et al., 1997). The different modes of action between
the local and systemic anaphylaxes could be attributed to the
difference in the route of antibody delivery and the anatomical
localization of mast cells and basophils. In PCA, IgG1 antibodies
are directly delivered into the skin tissue wheremast cells but not
basophils reside. Immune complexes are formed locally in the
skin lesions after the allergen challenge and stimulate tissue-res-
ident mast cells. In systemic anaphylaxis, the antibodies are de-
livered into the blood stream where basophils but not mast cells
are circulating. Immune complexes are formed within blood ves-
sels immediately after intravenous administration of allergens,
quickly trapped by basophils and other cells in the circulation
and spleen, and may not be delivered sufficiently into peripheral
tissues wheremast cells reside. Interestingly, the phenotypic dif-
ference was observed even between IgG1- and IgE-mediated
systemic anaphylaxis, most probably reflecting the different
anatomical localization of basophils and mast cells. Increased
Table 1. A Critical Role of Basophils in Active Systemic
Anaphylaxis
Mice Treatment Mortality Rate
WBB6F1-Kitw/w-v control IgG 12/12
WBB6F1-Kitw/w-v Ba103 0/10
C57BL/6-Kitw-sh/w-sh control IgG 4/4
C57BL/6-Kitw-sh/w-sh Ba103 0/4
C57BL/6 control IgG 12/12
C57BL/6 Ba103 10/10
Immunity
Basophils Elicit Anaphylaxis via IgG but Not IgEvascular permeability during systemic anaphylaxis, as detected
by dye extravasation, was more prominent in the trunk rather
than the periphery such as ears and foot pads in IgG1-mediated
anaphylaxis compared to IgE-mediated one (data not shown).
We previously showed that basophils play a critical role in
the development of IgE-mediated chronic allergic inflammation
in the skin (Mukai et al., 2005; Obata et al., 2007). Intradermal
injection of allergens induced three waves of ear swelling, with
a peak within 30 min, several hr, and 4 days, respectively, after
the allergen challenge in mice passively sensitized with aller-
gen-specific IgE or those with the IgE transgene. Although all
the allergic responses are mediated by IgE and Fc3RI, the first
and second ones are mast cell dependent, whereas the third
one with massive infiltration of eosinophils is basophil depen-
dent. In the present study, we demonstrated that basophils
play a pivotal role in IgG1-mediated but not IgE-mediated
systemic anaphylaxis. Thus, basophils critically contribute to
both the IgE-mediated chronic local allergic response and
the IgG1-mediated systemic allergic response. On the basis
of these findings, the following model can be proposed:
When allergens (or pathogens in a physiological process) enter
across the skin barrier in allergen-sensitized animals, mast
cells in the skin first elicit immediate-type allergic responses
against them. If these responses are not sufficient for their
elimination, basophils infiltrate into the skin tissue and elicit
a chronic inflammation with massive infiltration of other inflam-
matory cells such as eosinophils and neutrophils. When aller-
gens (or pathogens) invade into the blood stream, mast cells
and basophils induce massive and systemic responses against
them in an IgE- and IgG-dependent manner, respectively.
Larger amounts of allergens and antibodies are necessary to
induce the IgG-mediated anaphylaxis than the IgE-mediated
one (Strait et al., 2006).
Is the alternative pathway of systemic anaphylaxis mediated
by basophils, IgG, and PAF operative in humans, beside the
classical pathway? No definitive evidence for this has been
provided. However, it is notable that several case reports men-
tion human anaphylaxis, particularly in clinical settings such as
medication, that occurred in the apparent absence of detectable
allergen-specific IgE in serum or in the absence of increase in
serum tryptase levels; this increased serum tryptase level is a
reliable indicator of mast cell degranulation (Cheifetz et al.,
2003; Dybendal et al., 2003). Allergen-specific IgG antibodies
instead of IgE were detected in individuals who manifested
systemic anaphylaxis against medicines such as protamine,
dextran, and recombinant IgG (Adourian et al., 1993; Cheifetz
et al., 2003; Kraft et al., 1982; Weiss et al., 1989). Human baso-
phils were reported to release PAF upon activation with various
stimuli, although IgG immune complexes were not analyzed for
their ability to induce PAF release from human basophils (Lie
et al., 2003). Therefore, it would be worthwhile to assess the
possible involvement of basophils and PAF in human cases of
anaphylaxis, particularly those with high levels of serum IgG
but not IgE specific to a relevant allergen.
In conclusion, we have defined a previously unknown in vivo
function of basophils, distinct from that played by mast cells,
in the development of allergen-induced systemic anaphylaxis.
Basophils but not macrophages are the prime player in IgG-
mediated systemic anaphylaxis. This finding contrasts twomajor distinct pathways leading to systemic anaphylaxis: one
is mediated by basophils, IgG, IgG receptor, and PAF and the




C57BL/6 mice andmast-cell-deficient WBB6F1-KitW/W-v mice (Kitamura et al.,
1978) were purchased from CLEA Japan and SLC, respectively. Mast-cell-de-
ficient C57BL/6-KitW-sh/W-shmice (Grimbaldeston et al., 2005) weremaintained
in our animal facilities under specific pathogen-free conditions. All the exper-
iments in this studywere performed according to theGuidelines for Animal Use
and Experimentation, as set out by Tokyo Medical and Dental University.
Reagents
PenV-conjugated OVA and BSA were prepared with Na+BO3
2 buffer, as
described (Park et al., 1997). PenV-specific IgG1-mAb-secreting hybridomas
were established from splenocytes isolated from WBB6F1-KitW/W-v mice
that were immunized intraperitoneally with PenV-OVA together with alum
and B. pertussis toxin and 2 weeks later boosted with intravenous injection
of PenV-BSA. A basophil-depleting mAb Ba103 was established as described
(Obata et al., 2007). FITC-conjugated mAbs specific for c-kit (2B8), CD11c
(HL3), and CD33 (145-2C11), PE-conjugated mAbs specific for Siglec F
(E50-2440), CD19 (1D3), and CD11b (M1/70), biotinylated mAbs specific for
CD49b (DX5), c-kit (2B8), and IgE (R35/72), and allophycocyanin (APC)-conju-
gated streptavidin were purchased from BD PharMingen. FITC-conjugated
mAbs specific for CD49b (DX5), F4/80 (BM8), and Gr-1 (RB6-8C5), PE-conju-
gated anti-Fc3RIa (MAR-1), and biotinylated anti-F4/80 (BM8) were purchased
from eBioscience. Anti-FcgRII-III (2.4G2), anti-Gr-1 (RB6-8C5), and anti-NK1.1
(PK136) were prepared from hybridoma culture supernatants in our laborato-
ries. CV6209, cyproheptadine, PAF, and purified rat IgG were purchased from
Sigma-Aldrich. Liposomes containing dichloromethylene bisphosphonate
(clodronate-liposomes) were prepared as described (Endo et al., 1995; Van
Rooijen and Sanders, 1994).
Induction of Systemic Anaphylaxis
To induce passive anaphylaxis, mice (C57BL/6, C57BL/6-KitW-sh/W-sh, and
WBB6F1-KitW/W-v) were sensitized with an intravenous injection of 500 mg
PenV-specific IgG1 mAb, TNP-specific IgG1 mAb (ATCC TIB-191), or 50 mg
TNP-specific IgE mAb (IGELb4) (Rudolph et al., 1981) in 0.2 ml PBS. Three
hours after IgG injection or 24 hr after IgE injection, mice were intravenously
challenged with 1 mg PenV-BSA or 50 mg TNP8-BSA in 0.2 ml PBS. In some
experiments, mice were pretreated with i.p. injection of 100 mg CV6209 or
50 mg cyproheptadine. To induce active anaphylaxis, mice were primed by
intraperitoneal injection of 0.5 mg PenV-OVA (or TNP-OVA) and 1 mg of
alum together with subcutaneous injection of 300 ng of B. pertussis toxin.
Fourteen days later, mice were challenged with intravenous injection of
100 mg PenV-BSA (or TNP-BSA) in 0.2 ml PBS. Their rectal temperature was
measured with a digital thermometer (Shibaura Electronics).
In Vivo Depletion of Particular Cell Lineages
Forbasophil depletion,miceweregivenan intravenous injectionof100mgBa103
1 daybefore the antigen challenge (Obata et al., 2007). For neutrophil and eosin-
ophil depletion, mice were given an intraperitoneal injection of 2 mg anti-Gr-1 2
days before the antigen challenge. For macrophage depletion, mice were given
an intraperitoneal injection of 0.5ml clodronate-liposomes 2 days before the an-
tigenchallengeand thengiven an intravenous injection of 0.2ml clodronate-lipo-
somes the next day (Endo et al., 1995; Van Rooijen and Sanders, 1994). For NK
cell depletion, mice were given two intraperitoneal injections of 250 mg of anti-
NK1.1: one 48 hr and one 8 hr before the antigen challenge.
Flow Cytometry
We preincubated cells with anti-FcgRII-III and normal rat serum on ice for 15
min prior to incubation with the indicated combination of Abs, to prevent the
nonspecific binding of irrelevant Abs unless otherwise stated. Stained cells
were analyzed with a FACSCalibur (BD Biosciences). To detect IgE receptors,Immunity 28, 581–589, April 2008 ª2008 Elsevier Inc. 587
Immunity
Basophils Elicit Anaphylaxis via IgG but Not IgEwe incubated cells with IgE at 4C for 30 min to saturate the IgE receptors and
then stained them with anti-IgE. To detect IgG1-antigen complexes bound
to the cell surface in IgG1-sensitized mice, we prepared single suspensions
of cells from the indicated organs immediately after the intravenous injection
of biotinylated antigens and stained them with APC-streptavidin and the
indicated mAbs.
Fractionation of Spleen and Peritoneal Cells
For separation of the CD49b+ and CD49b fractions, spleen cells were reacted
with biotinylated anti-CD49b at 4C for 30 min, subsequently incubated with
streptavidin-conjugated BD IMag magnetic particles (BD PharMingen) for 30
min, and subjected to cell separation with the BD IMag Cell Separation Sys-
tem. Macrophages and mast cells were isolated from peritoneal cells with
the BD IMag System with biotinylated anti-F4/80 and anti-c-kit, respectively.
Measurement of PAF and Its Bioactivity
Cells (2 3 106 cells/0.5 ml) were incubated with 0.2 mg/ml of IgG1 alone or
IgG1 plus 0.4 mg/ml of allergen at 37C for 20 min in buffer containing
4.2 mM HEPES/NaOH (pH 7.4), 2.6 mM KCl, 137 mM NaCl, 5.6 mM glucose,
0.25% BSA, 1.3 mM CaCl2, and 1 mM MgCl2. Culture supernatants were
collected and mixed with 1.875 ml of chloroform:methanol (1:2, v/v), and
PAF-containing lipids were extracted as described (Bligh and Dyer, 1959).
The quantity of PAF was determined by competitive binding assay (Shindou
et al., 2000). To examine PAF bioactivity, we incubated cells with IgG1 plus
antigen as above, but in PBS. Culture supernatants were collected and
transferred to the culture wells containing a semiconfluent layer of HUVECs
that were untreated or pretreated with 1 mM CV-6209 at 37C for 5 min prior
to the addition of the culture supernatants. After a half-hour culture at 37C,
the HUVECs were fixed with 3% formaldehyde in PBS, permeabilized with
0.2% Triton X-100 in PBS, and stained for F-actin with Alexa-594-labeled
phalloidin. The specimens were examined by microscopy for that morpholog-
ical changes in the cells could be identified.
SUPPLEMENTAL DATA
Three figures are available at http://www.immunity.com/cgi/content/full/28/4/
581/DC1/.
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